Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study

RT @ATRIUMRx: Top Tweets from 2019: I'm still astounded by the cost of andexanet alfa. 4F-PCC appears to have similar safety/efficacy and…

RT @ATRIUMRx: Top Tweets from 2019: I'm still astounded by the cost of andexanet alfa. 4F-PCC appears to have similar safety/efficacy and…

RT @ATRIUMRx: Top Tweets from 2019: I'm still astounded by the cost of andexanet alfa. 4F-PCC appears to have similar safety/efficacy and…

RT @ATRIUMRx: Top Tweets from 2019: I'm still astounded by the cost of andexanet alfa. 4F-PCC appears to have similar safety/efficacy and…

Top Tweets from 2019: I'm still astounded by the cost of andexanet alfa. 4F-PCC appears to have similar safety/efficacy and is much, MUCH less expensive! https://t.co/njd7HwUuA2

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

When pointing out the limitations of this paper, please simultaneously point out limitations of ANNEXA-4, which is the whole reason why this paper is useful in the first place.

RT @accpcritprn: 4F-PCC for reversal of factor Xa inhibitors and a comparison to andexanet alfa #critPRN https://t.co/ArgR4Qyu8P

RT @accpcritprn: 4F-PCC for reversal of factor Xa inhibitors and a comparison to andexanet alfa #critPRN https://t.co/ArgR4Qyu8P

RT @accpcritprn: 4F-PCC for reversal of factor Xa inhibitors and a comparison to andexanet alfa #critPRN https://t.co/ArgR4Qyu8P

RT @accpcritprn: 4F-PCC for reversal of factor Xa inhibitors and a comparison to andexanet alfa #critPRN https://t.co/ArgR4Qyu8P

RT @accpcritprn: 4F-PCC for reversal of factor Xa inhibitors and a comparison to andexanet alfa #critPRN https://t.co/ArgR4Qyu8P

RT @accpcritprn: 4F-PCC for reversal of factor Xa inhibitors and a comparison to andexanet alfa #critPRN https://t.co/ArgR4Qyu8P

@DeloneyPruittl @KyleWeant

4F-PCC for reversal of factor Xa inhibitors and a comparison to andexanet alfa #critPRN https://t.co/ArgR4Qyu8P

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @EMCCC2: #Kcentra (#PCC) for #bleeding due to oral fXa inhibitors provides hemostasis in 80.6% of patients. Most had #ICH and received 5…

Also, 58% of the patient population in this study had an ICH! Interesting to see PCC showing good efficacy and no thrombotic events (median 7.2 days) in these high risk patients that many are reserving Andexxa for. 👍🏻

#Kcentra (#PCC) for #bleeding due to oral fXa inhibitors provides hemostasis in 80.6% of patients. Most had #ICH and received 50 units/kg. 0% developed #thrombotic event in hospital. Use of Kcentra instead of #Andexxa could save ~$50k per patient. https://

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

@AltshulerDiana @TaniaAhuja https://t.co/jEz6yATEex

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study | SpringerLink https://t.co/8kbejNMMpS

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

Four Factor Prothrombin Complex In patient with Factor Xa inhibitors related bleeding @accpcardprn @accpambuprn

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @PharmD_intheED: I’ve been telling everyone about this since SCCM. Excited to check this out https://t.co/uj0QKfcFGb

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @PharmD_intheED: I’ve been telling everyone about this since SCCM. Excited to check this out https://t.co/uj0QKfcFGb

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @PharmD_intheED: I’ve been telling everyone about this since SCCM. Excited to check this out https://t.co/uj0QKfcFGb

Great job Melanie @Tribidibidy Very timely

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

I’ve been telling everyone about this since SCCM. Excited to check this out

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

RT @Tribidibidy: 80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add…

80% efficacy and no thrombotic events for PCC based reversal. This hot off the press pub outlines why we chose not to add Andexxa to formulary. https://t.co/yI6UnMg0yV @accpcritprn @SCCM #PharmICU #critPRN https://t.co/TrQCF5WrDQ